Back

Mapping and ablation of slow conduction potentials as an effective end-point of ischemic ventricular tachycardia ablation: a novel approach

17 March 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Clinical case corner 1 - Ventricular Arrhythmias and SCD Ablation of Ventricular Arrhythmias EHRA Premium Access EHRA 2019

About the speaker

Photo
Mr David Lan

Stern Cardiovascular Center, Memphis (United States of America)

7 More presentations in this session

Presentation thumbnail
Recurrences following ARVC-related VT ablation and the need for epicardial ablation in very long-term follow-up
Presentation thumbnail
Radiofrequency applications from the great cardiac vein facilitated successful catheter ablation in a challenging case with symptomatic frequent premature ventricular contraction
Doctor K. Fukumoto (Yokohama, JP)
Abstract
Presentation thumbnail
Pulmonary arterial pressure predicts heart failure decompensation from recent onset frequent premature ventricular complexes: improvement after radiofrequency catheter ablation
Doctor S. Man (Plymouth, GB)
Abstract Slides
Presentation thumbnail
Sympathetic nervous system modulation to abolish recurrent ventricular fibrillation & intractable coronary spasm
Doctor V. Malik (Adelaide, AU)
Abstract
Presentation thumbnail
Ablation of premature ventricular contractions originating from a diverticulum of the right ventricular outflow tract: a case report
Doctor L. Yang (Guiyang, CN)

Access the full session

Session thumbnail
Clinical case corner 1 - Ventricular Arrhythmias and SCD

The Event

Event poster

EHRA 2019

17 March - 19 March 2019
You may be interested in
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?
thumbnail
Congress Presentation
Case 1 - first choice treatment: antiarrhythmic drugs or catheter ablation?
thumbnail
Congress Presentation
Ablation is alternative to ICD therapy in post-myocardial infarction patients with haemodynamically well-tolerated sustained monomorphic VT and LVEF>40%: con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources